Indicaton

F2i is a first-in-class, non-kinase, protein-protein interaction inhibitor of aberrant fibroblast growth factor signalling pathway in invasive cancers

Therapeutic indications
Type of product
Table
  • Phase
    Discovery
  • Partnering status
    Not partnered